AR
GLUE icon

Advisory Research’s Monte Rosa Therapeutics GLUE Stock Holding History

Advisory Research’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$514K Sell
31,236
-31,984
-51% -$612K 0.06% 128
2025
Q4 		$991K Buy
+63,220
New +$852K 0.12% 108

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Advisory Research's GLUE Position: Q1 2026 in Review

Advisory Research reduced its Monte Rosa Therapeutics (GLUE) stake by 51% in Q1 2026, selling an estimated $612K and leaving 31,236 shares worth $514K. The position accounts for 0.06% of the portfolio, ranked #128.

Advisory Research first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. The position peaked at $991K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Advisory Research held 31,236 shares of Monte Rosa Therapeutics worth $514K as of Q1 2026.
  • Advisory Research sold 31,984 Monte Rosa Therapeutics shares in Q1 2026, an estimated $612K.
  • Monte Rosa Therapeutics made up 0.06% of Advisory Research's portfolio in Q1 2026, its #128 holding.
  • Advisory Research first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Advisory Research's Monte Rosa Therapeutics position peaked at $991K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Advisory Research's 13F filing for Q1 2026, filed 14 May 2026.